US/UK/Canada

Share

Contacts

  • Ulf Hannelius

    CEO


    Box 7349, SE-103 90 Stockholm
    +46 8 661 00 26
    +46 8 661 63 68
    https://www.diamyd.com

    • Links

    Quotes

    The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.
    Ulf Hannelius, CEO
    Our top strategic priority is to prepare for a marketing application for Diamyd®
    Ulf Hannelius, CEO
    Pick a time period -
    Tags ( Active)

    Fully recruited European Phase IIb trial with the diabetes vaccine Diamyd®

    All patients in Diamyd Medical's European Phase IIb trial DIAGNODE-2, where the diabetes vaccine Diamyd® (rhGAD65/alum) is given directly into the lymph node, are now randomized and the trial is thus fully recruited. In total, 109 of originally 106 planned patients are included. The patients will be followed for 15 months and topline results are expected in the third quarter next year.In the Phase IIb trial DIAGNODE-2, a total of three injections of the Diamyd® diabetes vaccine (or its placebo) are given to patients aged 12-24 years, recently diganosed with type 1 diabetes, in order to

    First intralymphatic trial with Diamyd® fully recruited

    The open trial DIAGNODE-1 is now fully recruited after 12 patients. Diamyd Medical, together with Professor Johnny Ludvigsson at Linköping University, Principal investigator and Sponsor, has decided to close the recruitment of patients in the DIAGNODE-1 trial to begin the follow-up of patients already now and focus on the larger follow-up trial DIAGNODE-2.According to the protocol, the trial may include about 15 patients and a decision has been taken to close the recruitment at these 12 patients to initiate follow-up of the patients and to prepare for the larger phase II trial DIAGNODE-2. 6-

    Clinical study with Diamyd Medical’s diabetes vaccine fully recruited

    All participants have been included in a Phase II clinical study, DIABGAD-1, in which Diamyd Medical’s diabetes vaccine Diamyd®, in a unique combination with other drugs, is tested in children and adolescents recently diagnosed with type 1 diabetes. The first results from the researcher initiated study will thereby be available in the beginning of 2015.The study, DIABGAD-1, which is the first study of its kind, combines the diabetes vaccine Diamyd® with vitamin D and the anti-inflammatory drug ibuprofen. The Phase II study also evaluates the effect of a double dose of Diamyd® and the

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media